Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 45.1% in December

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totaling 2,118,631 shares, a growth of 45.1% from the December 15th total of 1,459,615 shares. Based on an average daily trading volume, of 1,301,783 shares, the short-interest ratio is currently 1.6 days. Currently, 5.7% of the shares of the stock are sold short. Currently, 5.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,301,783 shares, the short-interest ratio is currently 1.6 days.

Werewolf Therapeutics Stock Down 0.3%

Shares of Werewolf Therapeutics stock opened at $0.55 on Friday. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. The stock has a 50-day moving average price of $0.83 and a 200 day moving average price of $1.23. Werewolf Therapeutics has a 1 year low of $0.53 and a 1 year high of $2.38. The company has a market cap of $26.66 million, a P/E ratio of -0.34 and a beta of 0.77.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. As a group, analysts expect that Werewolf Therapeutics will post -1.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on HOWL shares. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Wedbush lowered shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target for the company. in a research report on Friday, December 19th. HC Wainwright lowered their price objective on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Citigroup lowered shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, December 19th. Finally, Bank of America decreased their target price on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Three analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $3.75.

Insider Transactions at Werewolf Therapeutics

In other Werewolf Therapeutics news, Director Luke Evnin sold 58,980 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $0.57, for a total transaction of $33,618.60. Following the completion of the transaction, the director directly owned 2,309,869 shares in the company, valued at approximately $1,316,625.33. This represents a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 5,980,336 shares of company stock valued at $6,503,824. 23.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

Several institutional investors have recently added to or reduced their stakes in HOWL. Bank of America Corp DE increased its position in shares of Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares in the last quarter. Vanguard Group Inc. raised its stake in Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after buying an additional 109,796 shares during the period. Jane Street Group LLC bought a new position in Werewolf Therapeutics in the 2nd quarter valued at about $409,000. Citadel Advisors LLC bought a new position in Werewolf Therapeutics in the third quarter valued at about $304,000. Finally, Marshall Wace LLP bought a new position in Werewolf Therapeutics during the 2nd quarter worth approximately $113,000. 64.84% of the stock is owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.